featured
2023 Top Story in Dermatology: Efficacy and Managing Long-Term Use of Dupilumab
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Valente C, Farinha P, Duarte B. Extending dupilumab dosing intervals in atopic dermatitis: a prospective observational study in a South European tertiary hospital. J Eur Acad Dermatol Venereol. 2023 Sep 20. doi: 10.1111/jdv.19528. Online ahead of print.
- Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23-32.
- Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159(5):526-535.
- Ardern-Jones MR, Buchanan EE, Njungu S, et al. Successful dose reduction of dupilumab in atopic dermatitis. Br J Dermatol. 2023;188(5):678-679.
Disclosure statements are available on the authors' profiles: